拉帕替尼-tykerb-患者使用指南-英文版
拉帕替尼-tykerb-患者使用指南-英文版
--------------------- DOSAGE FORMS AND STRENGTHS --------------
250 mg tablets (3)
------------------------------- CONTRAINDICATIONS ------------------------
Known severe hypersensitivity (e.g., anaphylaxis) to this product or any of its
components. (4)
----------------------- WARNINGS AND PRECAUTIONS ----------------
Decreases in left ventricular ejection fraction (LVEF) have been reported.
Confirm normal LVEF before starting TYKERB and continue evaluations
during treatment. (5.1)
Lapatinib has been associated with hepatotoxicity. Monitor liver function
tests before initiation of treatment, every 4 to 6 weeks during treatment,
and as clinically indicated. Discontinue and do not restart TYKERB if
patients experience severe changes in liver function tests. (5.2)
Dose reduction in patients with severe hepatic impairment should be
considered. (2.2, 5.3, 8.7)
Diarrhea, including severe diarrhea, has been reported during treatment.
Manage with anti-diarrheal agents, and replace fluids and electrolytes if
severe. (5.4)
Lapatinib has been associated with interstitial lung disease and
pneumonitis. Discontinue TYKERB if patients experience severe
pulmonary symptoms. (5.5)
Lapatinib may prolong the QT interval in some patients. Consider ECG
and electrolyte monitoring. (5.6, 12.4)
Fetal harm can occur when administered to a pregnant woman. Women
should be advised not to become pregnant when taking TYKERB. (5.7)
------------------------------ ADVERSE REACTIONS -----------------------
The most common (>20%) adverse reactions during treatment with TYKERB
plus capecitabine were diarrhea, palmar-plantar erythrodysesthesia, nausea,
rash, vomiting, and fatigue. The most common (≥20%) adverse reactions
during treatment with TYKERB plus letrozole were diarrhea, rash, nausea,
and fatigue. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact
GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or
doc.guandang.net.
------------------------------- DRUG INTERACTIONS ------------------------
TYKERB is likely to increase exposure to concomitantly administered
drugs which are substrates of CYP3A4, CYP2C8, or P-glycoprotein
(ABCB1). (7.1)
Avoid strong CYP3A4 inhibitors. If unavoidable, consider dose reduction
of TYKERB in patients coadministered a strong CYP3A4 inhibitor.
(2.2, 7.2)
Avoid strong CYP3A4 inducers. If unavoidable, consider gradual dose
increase of TYKERB in patients coadministered a strong CYP3A4
inducer. (2.2, 7.2)
See 17 for PATIENT COUNSELING INFORMATION and FDA-
approved patient labeling.
Revised: 10/2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TYKERB safely and effectively. See full prescribing information for TYKERB. TYKERB (lapatinib) tablets, for oral use Initial U.S. Approval: 2007 WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity has been observed in clinical trials and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain [see Warnings and Precautions (5.2)]. --------------------------- RECENT MAJOR CHANGES -------------------- Indication and Usage (1) 10/2013 Dosage and Administration, Dose Modification Guidelines (2.2) 12/2012 Warnings and Precautions, Diarrhea (5.4) 06/2013 ----------------------------INDICATIONS AND USAGE --------------------- TYKERB, a kinase inhibitor, is indicated in combination with: (1) capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitation of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. ----------------------- DOSAGE AND ADMINISTRATION ---------------- The recommended dosage of TYKERB for advanced or metastatic breast cancer is 1,250 mg (5 tablets) given orally once daily on Days 1-21 continuously in combination with capecitabine 2,000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21-day cycle. (2.1) The recommended dose of TYKERB for hormone receptor-positive, HER2-positive metastatic breast cancer is 1,500 mg (6 tablets) given orally once daily continuously in combination with letrozole. When TYKERB is coadministered with letrozole, the recommended dose of letrozole is 2.5 mg once daily. (2.1) TYKERB should be taken at least one hour before or one hour after a meal. However, capecitabine should be taken with food or within 30 minutes after food. (2.1) TYKERB should be taken once daily. Do not divide daily doses of TYKERB. (2.1, 12.3) Modify dose for cardiac and other toxicities, severe hepatic impairment, diarrhea, and CYP3A4 drug interactions. (2.2)
FULL PRESCRIBING INFORMATION: CONTENTS*
WARNING: HEPATOTOXICITY
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosing
2.2 Dose Modification Guidelines
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Decreased Left Ventricular Ejection Fraction
5.2 Hepatotoxicity
5.3 Patients With Severe Hepatic Impairment
5.4 Diarrhea
5.5 Interstitial Lung Disease/Pneumonitis
5.6 QT Prolongation
5.7 Use in Pregnancy
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience 7 8 10 11 12 6.2Postmarketing ExperienceDRUG INTERACTIONS 7.1 Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems 7.2 Drugs That Inhibit or Induce Cytochrome P450 3A4 Enzymes 7.3 Drugs That Inhibit Drug Transport Systems 7.4 Acid-Reducing Agents USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 8.7 Hepatic Impairment OVERDOSAGE DESCRIPTION
CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
泰立沙(Tykerb)拉帕替尼(lapatinib)相关指南、规范与共识、关键临床研究回顾_医药卫生_专业资料。泰立沙(Tykerb)拉帕替尼(lapatinib)相关指南、规范与共识、关键临床...
bd98bd0301f69e31423294142015小升初英语复习备考总复习课件 2015小升初六年级... 拉帕替尼-tykerb-患者使... 27页 免费 拉帕替尼的生产工艺设计 暂无评价 ...
整理打印装订课程设计说明书等有关资料 合计 所用...(对甲苯磺酸盐) 英文名:lapatinib ditosylate ... 拉帕替尼-tykerb-患者使... 27页 免费 吉非替...
(4):3 17—320 317 拉帕替尼合成工艺研究 张...商 品名为 Tykerb,化 学名 为Ⅳ.〔3一 氯一 4... HER2、 激素受体阳性的转移性乳腺癌绝经期患者。 ...
( 4 - 甲基苯磺酸盐 ) 一水化合物 ; 英文化学... 其作 用机 制 是抑制细胞内的 EGFR( ErB1) ... 拉帕替尼-tykerb-患者使... 27页 免费 拉帕替...
泰立沙(Tykerb)拉帕替尼(l... 56页 1财富值 ...患者的治愈机率成反比,即患者的癌细胞若带有第二型... 使用一键分享,轻松赚取财富值, 了解详情 嵌入播放...
厄洛替尼(erlotinibhydrochloride/TarcevaOSI、Genentech、 monohydrate/Tykerb,以下...试验中拉帕替尼合用卡培他滨和单用卡培他滨两组因 副反应而中止治疗患者比例...
新型抗肿瘤药二对甲苯磺酸拉帕替尼及其临床特点和市场潜力_专业资料。二对甲苯磺酸拉帕替尼单水合物(lapatinib distosylate monohydrate/Tykerb,以下简称为拉帕替尼)是...
早期乳腺癌患者拉帕替尼... 暂无评价 2页 免费 泰立沙(Tykerb)拉帕替尼...... 小学英语教学教研工作总结2014 Baidu 使用百度前必读 文库协议...
一项研究针对不能使用曲妥珠单抗的 HER-2 阳性早期乳腺癌患者,旨在确认其诊断 ...生物制剂拉帕替尼(tykerb)联合卡培他滨(希罗达)化 疗可治疗 HER2 阳性乳腺癌...
热门文档